VITALIY GAVRYLYUK: Open Payments
NPI 1639635790 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,094 in 47 payments from 11 companies in 2025. Trend: 2023 $942 · 2024 $1,135 · 2025 $1,094
Food & beverage: $1,094
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 14 | $263 |
| ABBVIE INC. | 9 | $250 |
| Alnylam Pharmaceuticals Inc. | 6 | $195 |
| Merck Sharp & Dohme LLC | 8 | $177 |
| Novartis Pharmaceuticals Corporation | 3 | $60 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| Boston Scientific Corporation | 1 | $33 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
| AtriCure, Inc. | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $18 |
Products named: REPATHA, AMVUTTRA, CREON, VERQUVO, LINZESS, LEQVIO, XIFAXAN, Varithena Administration Pack.
Industry payments across NY — which companies pay providers there.
